{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:29:30Z","timestamp":1761974970725},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.det.2006.06.008","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:06:46Z","timestamp":1168441606000},"page":"459-472","source":"Crossref","is-referenced-by-count":27,"title":["Adverse Cutaneous Drug Eruptions and HIV: a Clinician's Global Perspective"],"prefix":"10.1016","volume":"24","author":[{"given":"Gail","family":"Todd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2006.06.008_bib1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1529-8019.2005.05004.x","article-title":"Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients","volume":"18","author":"Kong","year":"2005","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2006.06.008_bib2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.iac.2004.03.006","article-title":"HIV and drug allergy","volume":"24","author":"Temesgen","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.det.2006.06.008_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00015550310002611","article-title":"Severe cutaneous reactions associated with the use of human immunodeficiency virus medications","volume":"83","author":"Rotunda","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2006.06.008_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1067\/mjd.2002.119105","article-title":"Cutaneous manifestations of antiretroviral therapy","volume":"46","author":"Ward","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00130832-200108000-00006","article-title":"HIV and drug allergy","volume":"1","author":"Pirmohamed","year":"2001","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.det.2006.06.008_bib6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199306103282304","article-title":"Cutaneous disease and drug reactions in HIV infection","volume":"328","author":"Coopman","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2006.06.008_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00128071-200304060-00005","article-title":"Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions: implications for management","volume":"4","author":"Crowson","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.det.2006.06.008_bib9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib10","first-page":"357","article-title":"The drug hypersensitivity syndrome. What is the pathogenesis?","volume":"137","author":"Sullivan","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib11","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.det.2006.06.008_bib12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0190-9622(85)70156-9","article-title":"Cutaneous drug reactions: pathogenesis and clinical classification","volume":"13","author":"Wintroub","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib14","first-page":"1","article-title":"Cutaneous reactions to drugs with special reference to severe bullous mucocutaneous eruptions and sulphonamides","volume":"68","author":"Kauppinen","year":"1972","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2006.06.008_bib15","first-page":"1","article-title":"International drug monitoring: the role of national centres","volume":"498","author":"World Health Organization","year":"1972","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.det.2006.06.008_bib16","series-title":"International monitoring of adverse reactions to drugs: adverse reaction terminology","author":"World Health Organization","year":"1992"},{"key":"10.1016\/j.det.2006.06.008_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/pds.2630030105","article-title":"The medical dictionary for drug regulatory affairs (MEDRA)","volume":"3","author":"Wood","year":"1994","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.det.2006.06.008_bib18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.det.2006.06.008_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-140-10-200405180-00017","article-title":"Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting","volume":"140","author":"Nebeker","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.det.2006.06.008_bib20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/archinte.161.8.1041","article-title":"Drug-related adverse events. A readers' guide to assessing literature reviews and meta-analyses","volume":"161","author":"Ross","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.det.2006.06.008_bib21","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/bmj.327.7425.1222","article-title":"Joining the DoTS: new approach to classifying adverse drug reactions","volume":"327","author":"Aronson","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.det.2006.06.008_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.det.2006.06.008_bib23","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1365-2133.2003.05584.x","article-title":"A 6-month prospective survey of cutaneous drug reactions in a hospital setting","volume":"149","author":"Fiszenson-Albala","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00128071-200203040-00001","article-title":"Cellular and molecular pathophysiology of cutaneous drug reaction","volume":"3","author":"Pichler","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib25","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1034\/j.1398-9995.2002.02161.x","article-title":"Pathogenesis of drug-induced exanthems","volume":"57","author":"Pichler","year":"2002","journal-title":"Allergy"},{"key":"10.1016\/j.det.2006.06.008_bib26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00002018-200023060-00002","article-title":"Immunological principles of adverse drug reactions. The initiation and propagation of immune responses elicited by drug treatment","volume":"23","author":"Naisbitt","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.det.2006.06.008_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/tx980249i","article-title":"New concepts in immunology relevant to idiosyncratic drug reactions: the \u201cdanger hypothesis\u201d and innate immune system","volume":"12","author":"Uetrecht","year":"1999","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.det.2006.06.008_bib28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaci.2003.12.591","article-title":"Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003","volume":"113","author":"Johansson","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.det.2006.06.008_bib29","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib31","unstructured":"EuroSCAR. European study of severe cutaneous adverse drug reactions. Available at: http:\/\/www.b3e.jussieu.fr\/euroscar2\/menu.html. Accessed August 17, 2006."},{"key":"10.1016\/j.det.2006.06.008_bib32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/01.all.0000173785.81024.33","article-title":"Epidemiology of hypersensitivity drug reactions","volume":"5","author":"Gomes","year":"2005","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.det.2006.06.008_bib33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1081-1206(10)61804-2","article-title":"Drug allergy in a general hospital: results of a novel prospective inpatient reporting system","volume":"90","author":"Thong","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.det.2006.06.008_bib34","first-page":"574","article-title":"Adverse drug reactions in Singaporean children","volume":"45","author":"Kidson","year":"2004","journal-title":"Singapore Med J"},{"key":"10.1016\/j.det.2006.06.008_bib35","series-title":"The challenge of dermato-epidemiology","first-page":"329","article-title":"The epidemiology of serious cutaneous drug reaction","author":"Mockenhaupt","year":"1997"},{"key":"10.1016\/j.det.2006.06.008_bib36","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0733-8635(18)30073-1","article-title":"Epidemiology of adverse cutaneous reactions to drugs","volume":"13","author":"Stern","year":"1995","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.det.2006.06.008_bib37","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1001\/jama.1986.03380240052027","article-title":"Drug-induced cutaneous reaction. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982","volume":"256","author":"Bigby","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.det.2006.06.008_bib38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.1365-2230.1997.2130642.x","article-title":"Increased drug reactions in HIV-1 positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR)","volume":"22","author":"Smith","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib39","first-page":"531","article-title":"[Stevens-Johnson syndrome and toxic epidermal necrolysis in Lome (Togo). Evolutional and etiological profiles of 40 cases.]","volume":"132","author":"Pitche","year":"2005","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.det.2006.06.008_bib40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000247299","article-title":"Evolving pattern of drug-induced toxic epidermal necrolysis","volume":"186","author":"Correia","year":"1993","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2006.06.008_bib41","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","article-title":"Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"15","author":"Fagot","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.det.2006.06.008_bib42","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00126334-200402010-00003","article-title":"Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals","volume":"35","author":"Patel","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.det.2006.06.008_bib43","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.det.2006.06.008_bib44","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0140-6736(91)92447-A","article-title":"Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis","volume":"337","author":"Nunn","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.det.2006.06.008_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0962-8479(92)90079-Y","article-title":"Cross-sectional survey of HIV infection among patients with tuberculosis in Nairobi, Kenya","volume":"73","author":"Nunn","year":"1992","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.det.2006.06.008_bib46","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/adc.68.5.665","article-title":"Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-1","volume":"68","author":"Chintu","year":"1993","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.det.2006.06.008_bib47","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.healthpol.2005.01.006","article-title":"The cost to health services of human immunodeficiency virus (HIV) co-infection among tuberculosis patients in Sudan","volume":"75","author":"El-Sony","year":"2006","journal-title":"Health Policy"},{"key":"10.1016\/j.det.2006.06.008_bib48","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1034\/j.1398-9995.2003.00279.x","article-title":"Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations","volume":"58","author":"Aberer","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.det.2006.06.008_bib49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1365-4362.2001.01173-7.x","article-title":"Reintroducing antituberculosis therapy after Stevens-Johnson syndrome in human immunodeficiency virus-infected patients with tuberculosis: role of desensitisation","volume":"40","author":"Kura","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2006.06.008_bib50","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/323353","article-title":"Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reactions to TMP-SMZ","volume":"184","author":"Leoung","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.det.2006.06.008_bib51","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1081-1206(10)63338-8","article-title":"Successful oral desensitization to trimethoprim-sulfamethoxazole in acquired immune deficiency syndrome","volume":"77","author":"Kalanadhabhatta","year":"1996","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.det.2006.06.008_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.102.041624","article-title":"Inflammation and drug idiosyncrasy\u2014is there a connection?","volume":"307","author":"Roth","year":"2003","journal-title":"J\u00a0Pharmacol Exp Ther"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863506000635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863506000635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T17:19:04Z","timestamp":1556039944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863506000635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0733863506000635"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2006.06.008","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}